Jasper releases new data on briquilimab from SPOTLIGHT trial

Californian biotech Jasper Therapeutics (Nasdaq: JSPR) presented data from the 180mg cohort of the company’s SPOTLIGHT Phase Ib/IIa study of subcutaneous briquilimab in adult participants with chronic inducible urticaria (CIndU) at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress.

Briquilimab is a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as urticaria and asthma.

Briquilimab (subcutaneous) administration resulted in deep disease control at 180mg, with 12 of 12 participants (100%) enrolled in the cohort achieving a clinical response within the 8-week preliminary analysis period. The efficacy observed was rapid and durable, with 8 of 12 participants (66%) achieving clinical response by week 2, and 7 of 12 participants (58%) maintaining clinical response through week 8. Briquilimab continued to be well tolerated in the study, with no serious adverse events (SAEs) and no grade 3 or higher adverse events (AEs) reported in the 180mg cohort.